Findings from Semmelweis University Provide New Insights into Crohn’s Disease (Therapeutic preferences and outcomes in newly diagnosed patients with…

Managed Care Weekly Digest

Findings from Semmelweis University Provide New Insights into Crohn's Disease (Therapeutic preferences and outcomes in newly diagnosed patients with Crohn's diseases in the biological era in Hungary: a nationwide study based on the National ...)

By a News Reporter-Staff News Editor at Managed Care Weekly Digest -- Data detailed on Digestive System Diseases and Conditions - Crohn's Disease have been presented. According to news reporting from Budapest, Hungary, by NewsRx journalists, research stated, "Accelerated treatment strategy, including tight disease control and early aggressive therapy with immunosuppressives (IS) and biological agents have become increasingly common in inflammatory bowel disease (IBD). The aim of the present study was to estimate the early treatment strategy and outcomes in newly diagnosed patients with Crohn's disease (CD) between 2004 and 2008 and 2009-2015 in the whole IBD population in Hungary based on the administrative database of the National Health Insurance Fund (OEP)."

The news correspondents obtained a quote from the research from Semmelweis University, "We used the administrative database of the OEP, the only nationwide state-owned health insurance provider in Hungary. Patients were identified through previously reported algorithms using the ICD-10 codes for CD in the out-, inpatient (medical, surgical) non-primary care records and drug prescription databases between 2004 and 2015. Patients were stratified according to the year of diagnosis and maximum treatment steps during the first 3 years after diagnosis. A total of 6173 (male/female: 46.12%/53.87%) newly diagnosed CD patients with physician-diagnosed IBD were found in the period of 2004-2015. The use of 5-ASA and steroids remained common in the biological era, while immunosuppressives and biologicals were started earlier and became more frequent among patients diagnosed after 2009. The probability of biological therapy was 2.9%/6.4% and 8.4%/13.7% after 1 and 3 years in patients diagnosed in 2004-2008/2009-2015. The probability of hospitalization in the first 3 years after diagnosis was different before and after 2009, according to the maximal treatment step (overall 55.7% vs. 47.4% (p = 0.001), anti-TNF: 73% vs. 66.7% (p = 0.103), IS: 64.6% vs. 56.1% (p = 0.001), steroid: 44.2% vs. 36.8% (p < 0.007), 5-ASA: 32.6% vs. 26.7% p = 0.157)). In contrast, surgery rates were not significantly different in patients diagnosed before and after 2009 according to the maximum treatment step (overall 16.0% vs. 15.3%(p = 0.672) anti-TNF 26.7% vs. 27.2% (p = 0.993), IS: 24.1% vs22.2% (p = 0.565), steroid 8.1% vs. 7.9% (p = 0.896), 5-ASA 10% vs. 11% (p = 0.816)). IS and biological exposure became more frequent, while hospitalization decreased and surgery remained low but constant during the observation period. Use of steroids and 5-ASA remained high after 2009."

According to the news reporters, the research concluded: "The association between the maximal treatment step and hospitalization/surgery rates suggests that maximal treatment step can be regarded as proxy severity marker in patients with IBD."

For more information on this research see: Therapeutic preferences and outcomes in newly diagnosed patients with Crohn's diseases in the biological era in Hungary: a nationwide study based on the National Health Insurance Fund database. BMC Gastroenterology, 2018;18():9-17. BMC Gastroenterology can be contacted at: Biomed Central Ltd, 236 Grays Inn Rd, Floor 6, London WC1X 8HL, England. (BioMed Central - www.biomedcentral.com/; BMC Gastroenterology - www.biomedcentral.com/bmcgastroenterol/)

Our news journalists report that additional information may be obtained by contacting P.L. Lakatos, Semmelweis University, Div Gastroenterol Hepatol Unit & Endoscopy, H-1083 Budapest, Hungary. Additional authors for this research include A. Ilias, L. Gonczi, Z. Vegh, P. Fadgyas-Freyler, G. Korponay, P.A. Golovics, B.D. Lovasz and Z. Kurti (see also Digestive System Diseases and Conditions - Crohn's Disease).

Keywords for this news article include: Budapest, Hungary, Europe, Digestive System Diseases and Conditions, Gastrointestinal Diseases and Conditions, Diagnostics and Screening, Health and Medicine, Drugs and Therapies, Insurance Companies, Health Insurance, Gastroenterology, Hospitalization, Crohn's Disease, Gastroenteritis, Patient Care, Surgery, Semmelweis University.